

POLICY Document for PERJETA (pertuzumab)

The overall objective of this policy is to support the appropriate and cost effective use of the medication. This document provides specific information to each section of the overall policy.

Section 1: Clinical Criteria

- Policy information specific to the clinical appropriateness for the medication

Section 2: Oncology Clinical Policy

- Policy information specific to regimen review per NCCN Guidelines.

Section 1: Clinical Criteria

SPECIALTY GUIDELINE MANAGEMENT PERJETA (pertuzumab)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

a. FDA-Approved Indications

1. Metastatic breast cancer
In combination with trastuzumab and docetaxel for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
2. Neoadjuvant treatment of breast cancer
In combination with trastuzumab and chemotherapy as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer.
3. Adjuvant treatment of breast cancer
In combination with trastuzumab and chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.

b. Compendial Uses

Treatment of recurrent or stage IV (M1) human epidermal growth factor receptor 2 (HER2)-positive breast cancer

All other indications are considered experimental/investigational and are not a covered benefit.

Perjeta_SGM_NCCN_P2019

49891A FNL3 Oncology Clinical Policy.docx

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

© 2019 CVS Caremark. All rights reserved.

II. CRITERIA FOR INITIAL APPROVAL

Breast cancer

- a. Authorization of 6 months may be granted for neoadjuvant therapy of HER2-positive breast cancer.
- b. Authorization of 12 months may be granted for adjuvant therapy of HER2-positive breast cancer.
- c. Authorizations of 12 months may be granted for the treatment of recurrent or metastatic HER2-positive breast cancer.

III. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet ALL initial authorization criteria.

Section 2: Oncology Clinical Policy

Oncology Clinical Policy

Program Description

The National Comprehensive Care Network® (NCCN®) is an alliance of leading cancer centers devoted to patient care, research and education dedicated to improving the quality, effectiveness and efficiency of cancer care so patients can live better lives.¹ It is comprised of oncology experts who convene regularly to establish the best treatments for patients. NCCN develops various resources for use by stakeholders in the health care delivery system. These resources include, but are not limited to, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), the NCCN Drugs & Biologics Compendium (NCCN Compendium®) and the NCCN Chemotherapy Order Templates (NCCN Templates®).

NCCN templates are based on NCCN Clinical Practice Guidelines and NCCN Compendium. The NCCN Compendium lists the appropriate drugs and biologics for specific cancers using U.S. Food and Drug Administration (FDA)-approved disease indications and specific NCCN panel recommendations. Each recommendation is supported by a level of evidence category.

NCCN Categories of Evidence and Consensus²

- Category 1: Based on high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
- Category 2A: Based on lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
- Category 2B: Based on lower-level evidence, there is NCCN consensus that the intervention is appropriate.
- Category 3: Based any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

Policy for Regimen Prior Authorization

A regimen prior authorization allows submission of a single prior authorization request for all oncology drugs or biologics within an NCCN template that require prior authorization.

This policy provides coverage of a regimen review when *all* of the following criteria are met:

- a. Regimen prior authorization reviews, based on NCCN templates, are initiated through the provider portal: <https://provider.carefirst.com/providers/home.page>
- b. If the prior authorization request is submitted via phone or fax, each drug or biologic will need to be submitted and reviewed as a separate prior authorization request for review with drug-specific criteria.
2. The prior authorization review is requested for an oncology drug or biologic that requires prior authorization on the medical benefit.
3. The indication is for a cancer that is eligible for regimen review. Currently, the cancer types in scope for regimen review include breast, lung, colon and rectal cancer.
4. The member is eligible for regimen review.

In addition, the following criteria must be met for approval:

1. The requested regimen for the drug(s) or biologic(s) and indication is consistent with an NCCN recommendation with a level of evidence category of 1 or 2A.
2. The NCCN template must be accepted by the provider without modification.

Authorizations may be granted for 12 months.

Further review may be indicated where the above criteria are not met.

Continuation of Therapy

To submit a request for continuation of therapy, a new regimen prior authorization review must be requested. Upon template selection, the template must be modified to include the appropriate therapies being used for maintenance treatment. The regimen request will be submitted for further review.

Dosage and Administration

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia and/or evidence-based practice guidelines.

REFERENCES:

SECTION 1

1. Perjeta [package insert]. South San Francisco, CA: Genentech, Inc.; December 2018.
2. The NCCN Drugs & Biologics Compendium® © 2019 National Comprehensive Cancer Network, Inc. <https://www.nccn.org>. Accessed January 28, 2019.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 3.2018. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed January 26, 2019.

SECTION 2

1. National Comprehensive Cancer Network. About NCCN website. <https://www.nccn.org/about/default.aspx>, accessed September 16, 2019.
2. National Comprehensive Cancer Network. NCCN Categories of Evidence and Consensus website. https://www.nccn.org/professionals/physician_gls/categories_of_consensus.aspx, accessed September 16, 2019.
3. National Comprehensive Cancer Network. NCCN Guidelines website. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp, accessed September 16, 2019. (*Note: An account may be required.*)
4. National Comprehensive Cancer Network. NCCN Drugs and Biologics Compendium® website. http://www.nccn.org/professionals/drug_compendium/content/contents.asp, accessed September 16, 2019. (*Note: A subscription may be required.*)
5. National Comprehensive Cancer Network. NCCN Chemotherapy Order Templates (NCCN Templates) website. <https://www.nccn.org/professionals/OrderTemplates/Default.aspx>, accessed September 16, 2019. (*Note: A subscription may be required.*)